Literature DB >> 15601978

The long-term management of obesity with continuing pharmacotherapy.

Arthur Frank1.   

Abstract

OBJECTIVE: Long-term, possibly lifetime, use of medications for the management of obesity may be thought to be similar to the use of pharmacotherapy for other chronic diseases such as hypertension or diabetes. Because there have been no systematic studies of this extended use, the experience of eight patients who have used obesity medications in a sustaining manner was studied. RESEARCH METHODS AND PROCEDURES: The clinical characteristics of eight adult patients, each of whom has experience with long-term (more than 10 years) use of medications for weight loss and weight maintenance, were studied.
RESULTS: The clinical experience of these eight patients was analyzed. Each chose to sustain the use of weight management medications for more than 10 years because of perceived benefit, comfort, and the absence of significant side effects. There has been no evidence of the development of tolerance, addiction, or misuse and no adverse events related to the medication. The beneficial effects of the medication have not diminished with time. DISCUSSION: The clinical characteristics of eight patients, each of whom has used obesity pharmacotherapy for more than 10 years, are described. The experience of these eight individuals cannot be generalized to the entire population of overweight or obese patients. It does suggest, however, that some patients respond successfully to this form of therapy and that they will derive value from it for the management of this disease. Efforts should be made to identify these patients, and consideration should be given to the use of chronic medications for the continuing management of obesity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15601978     DOI: 10.1038/oby.2004.226

Source DB:  PubMed          Journal:  Obes Res        ISSN: 1071-7323


  6 in total

1.  Long-term pharmacotherapy for obesity in elderly patients: a retrospective evaluation of medical records from a specialized obesity outpatient clinic.

Authors:  Nídia Celeste Horie; Cintia Cercato; Marcio C Mancini; Alfredo Halpern
Journal:  Drugs Aging       Date:  2010-06-01       Impact factor: 3.923

2.  How physician obesity medicine specialists treated obesity before 2012 new drug approvals.

Authors:  Stacy L Schmidt; David Bryman; Frank L Greenway; Ed J Hendricks
Journal:  Obes Surg       Date:  2015-01       Impact factor: 4.129

3.  Effects of capsinoid ingestion on energy expenditure and lipid oxidation at rest and during exercise.

Authors:  Andrea R Josse; Scott S Sherriffs; Andrew M Holwerda; Richard Andrews; Aaron W Staples; Stuart M Phillips
Journal:  Nutr Metab (Lond)       Date:  2010-08-03       Impact factor: 4.169

4.  Addiction potential of phentermine prescribed during long-term treatment of obesity.

Authors:  E J Hendricks; M Srisurapanont; S L Schmidt; M Haggard; S Souter; C L Mitchell; D G De Marco; M J Hendricks; Y Istratiy; F L Greenway
Journal:  Int J Obes (Lond)       Date:  2013-05-17       Impact factor: 5.095

5.  RE: Pulmonary hypertension associated with use of phentermine?

Authors:  Ed J Hendricks; Richard B Rothman
Journal:  Yonsei Med J       Date:  2011-09       Impact factor: 2.759

Review 6.  Off-label drugs for weight management.

Authors:  Ed J Hendricks
Journal:  Diabetes Metab Syndr Obes       Date:  2017-06-10       Impact factor: 3.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.